The content on this site is intended for healthcare professionals only
Prof Jorge Reis-Filho talks to ecancer about molecularly characterising triple negative breast cancer at IMPAKT 2012 in Brussels, May 2012.
At the molecular level, triple negative breast cancer is not a single disease. There are a larger number of heterogeneous tumours, which means that this disease cannot be analysed in the same way as other types of breast cancer.
The differences between diseases are the biological starting point for testing different therapeutic agents against triple negative breast cancer. The different subtypes of tumours can each respond differently to strategies, but will give prognostic signatures that will point to a quick and clear prognosis. However, there are complications with what type of prognostic signatures can be used in triple negative cases.
Filming Supported by Amgen
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Relapsed refractory multiple myeloma
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
